RT Journal Article
SR Electronic
T1 Repurposing Colchicine for the Management of COVID-19: A Systematic Review and Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.17.21251884
DO 10.1101/2021.02.17.21251884
A1 Mohanty, Rashmi Ranjan
A1 Meher, Bikash Ranjan
A1 Padhy, Biswa Mohan
A1 Das, Smita
YR 2021
UL http://medrxiv.org/content/early/2021/02/19/2021.02.17.21251884.abstract
AB Many anti-inflammatory drugs like, tocilizumab, N-acetylcystiene and etolizumab has been repurposed for the management of COVID-19 with variable success. Colchicine exhibits anti-inflammatory activity by tubulin disruption and inhibition of leucocyte-mediated inflammatory activities like production of superoxide and release of various cytokines which are central to the pathophysiology of COVID-19. So, this systematic review and meta-analysis assessed the currently available data on the use of colchicine for the treatment of COVIDLJ19. A total of 3 studies (2 RCTS and 1 observational study) including 402 patients were included out of which 194 patients received colchicine. The random effect model showed the overall pooled OR to be 0.32 (95%CI: 0.18 to 0.56) for the primary outcome (Clinical deterioration) which was statistically significant (p <0.0001). Also there was increase in adverse effect (diarrhoea) with use of colchicine as suggested by the pooled OR (OR=4.56, 95%CI: 2.04 to 10.15, P=0.0002). With the limited number of available studies, it has shown statistically significant reduction in clinical deterioration in COVID-19. Though there was an increase in adverse effect in the form of diarrhoea, it was mild and self-limiting.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.crd.york.ac.uk/prospero/ Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IEC, AIIMS, BhubaneswarAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data set has been available in pubMed AND medRxiv